| 000 | 01847 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514052435.0 | ||
| 264 | 0 | _c20021223 | |
| 008 | 200212s 0 0 eng d | ||
| 022 | _a1524-4539 | ||
| 024 | 7 |
_a10.1161/01.cir.0000049360.95556.57 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSoRelle, Ruth | |
| 245 | 0 | 0 |
_aBlood containing high levels of antibodies to heat shock protein 65 (hsp65) were found to be at increased risk of subsequent cardiovascular events. _h[electronic resource] |
| 260 |
_bCirculation _cNov 2002 |
||
| 300 |
_ae9052-8 p. _bdigital |
||
| 500 | _aPublication Type: News; Portrait; Comment | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Arrhythmia Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAnticoagulants _xtherapeutic use |
| 650 | 0 | 4 |
_aAutoantibodies _xblood |
| 650 | 0 | 4 | _aBacterial Proteins |
| 650 | 0 | 4 |
_aBlood Vessel Prosthesis Implantation _xadverse effects |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xblood |
| 650 | 0 | 4 | _aChaperonin 60 |
| 650 | 0 | 4 |
_aChaperonins _ximmunology |
| 650 | 0 | 4 |
_aCholesterol _ximmunology |
| 650 | 0 | 4 |
_aClinical Trials as Topic _xstatistics & numerical data |
| 650 | 0 | 4 |
_aComplement Inactivator Proteins _xtherapeutic use |
| 650 | 0 | 4 |
_aCoronary Artery Bypass _xstandards |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aFiltration _xinstrumentation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNeoplasms _xchemically induced |
| 650 | 0 | 4 |
_aPatient Education as Topic _xmethods |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aStents _xadverse effects |
| 773 | 0 |
_tCirculation _gvol. 106 _gno. 22 _gp. e9052-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/01.cir.0000049360.95556.57 _zAvailable from publisher's website |
| 999 |
_c12257281 _d12257281 |
||